Allogeneic hematopoietic cell transplantation (alloHCT) remains a valuable treatment alternative for relapsed/refractory (R/R) Hodgkin lymphoma (HL). Data on alloHCT outcomes in the era of new HL therapies are needed. We evaluated 72R/R HL patients who received reduced intensity conditioning alloHCT and compared the time periods 2009-2013 (n = 20) with 2000-2008 (n = 52). Grafts included HLA-matched sibling (35%), unrelated donor (8%) and umbilical cord blood (56%). In the recent period, patients more often received brentuximab vedotin (BV, 60% vs 2%), had fewer comorbidities (Sorror index 0: 60% vs 12%) and were in complete remission (50% vs 23%). Median follow-up was 4.4 years. Three-year PFS improved for patients treated between 2009 and 2013 (49%, 95% CI 26-68%) as compared with the earlier era (23%, 95% CI 13-35%, P = 0.02). Overall survival (OS) at 3 years was 84% (95% CI 57-94%) vs 50% (95% CI 36-62%, P = 0.01), reflecting lower non-relapse mortality and relapse rates. In multivariate analysis mortality was higher among those with chemoresistance (HR 3.83, 95% CI 1.38-10.57), while treatment during the recent era was associated with better OS (HR for period 2009-2013: 0.24, 95% CI 0.07-0.79) and PFS (HR 0.46, 95% CI 0.23-0.92). AlloHCT in patients with R/R HL is now a more effective treatment than previously.
INTRODUCTION
Hodgkin lymphoma (HL) is curable in the majority of patients; however, upwards of 25% will fail standard front-line chemotherapy. 1, 2 For these patients, high-dose chemotherapy followed by autologous hematopoietic cell transplantation (autoHCT) can be curative but half will eventually relapse with poor prognosis. [3] [4] [5] Median survival of patients who relapse after autoHCT has historically been approximately 2 years. [6] [7] [8] Allogeneic hematopoietic transplantation (alloHCT) has been applied for patients with advanced HL who relapse after autoHCT, are poorly responsive to chemotherapy or fail to provide an adequate autologous graft. Reduced intensity conditioning (RIC) regimens decreased nonrelapse mortality after alloHCT as compared with myeloablative conditioning and are now widely applied for HL. [9] [10] [11] [12] Brentuximab vedotin (BV), an anti-CD30 targeting antibody-drug conjugate, has been studied for relapsed/refractory (R/R) HL since 2009 13 and demonstrated an overall response rate of 75% in patients relapsing after autoHCT. 14 Given this improvement in disease control and wider use of RIC and alternative donors, more patients with advanced HL can now be considered for a potentially curative alloHCT. [15] [16] [17] To guide treatment decisions in the current era and to counsel patients in whom allograft is considered, we present updated data on survival after alloHCT from a single institution.
PATIENTS AND METHODS
Using prospectively collected data from the University of Minnesota Blood and Marrow Transplantation Database, we identified 72 consecutive patients with HL who underwent RIC alloHCT between 2000 and 2013. The review of all available medical records were supplemented by chart review for the use of BV therapy. To evaluate transplant outcomes over time, the 13-year period was divided into a historical cohort from 2000 to 2008 and more recent cohort during the BV era from 2009 to 2013. The University of Minnesota Institutional Review Board approved the study. Eligibility criteria included relapse after prior autoHCT or not being an autoHCT candidate because of insufficient stem cell collection or chemorefractory disease. RIC conditioning consisted of 200 cGy of TBI plus fludarabine 40 mg/m 2 /day IV for days − 6 through − 2 and either cyclophosphamide 50 mg/kg/day IV day − 6 (n = 60) or busulfan 1 mg/kg/day orally every 6 h days − 8 and − 7 (n = 12). Five patients received anti-thymocyte globulin. HLA-matched sibling donor, HLA-matched unrelated donor and umbilical cord blood (UCB) donor sources were included. Choice of donor was based on availability and institutional preference and experience with cord blood transplantation.
For GVHD prophylaxis, 69 patients received cyclosporine IV or orally targeting a therapeutic trough range of 200-400 mg/mL from day − 3 for a minimum for 100 days, followed by a taper thorough day +180. Mycophenolate mofetil (1 g IV or orally twice a day for 30 days) was increased to 1 g three times a day in 2006. 18 All patients received filgrastim (5 μg/kg/day IV) from day +1 until ANC ⩾ 2500/μL for 2 days. Comorbidities were scored according to the Sorror hematopoietic cell transplantation index (HCT-CI). 19 Acute and chronic GVHD were graded as extensive or limited prior to 2005 20 and by the NIH consensus criteria after 2005. 21 Disease evaluation using computed tomography, bone marrow biopsies and variable number of tandem repeats engraftment analysis occurred on day 30, day 100, and years 1 and 2 after transplantation. Positron emission tomography was routinely used to measure disease status prior to transplant after 2004 and all patients underwent a positron emission tomography scan at day 100. Disease response was scored using standard International Working Group criteria. 22 Patient and disease characteristics were summarized using descriptive statistics. Statistical comparisons of variables between the two groups were completed by nonparametric Wilcoxon test for continuous factors and Pearson χ 2 test for categorical factors. The end points were PFS, overall survival (OS), cumulative incidence of relapse (REL) and non-relapse mortality (NRM). The Kaplan-Meier method 23 was used to estimate the probabilities of PFS and OS, and the log-rank test was used for univariate comparisons between groups. Cumulative incidence estimator was used to calculate the probabilities of relapse reflecting nonevent deaths as a competing risk. The cumulative incidence of NRM was also calculated reflecting relapse as a competing risk. 24 Fine and Gray 25 regression analyses were used to compare the differences between cumulative incidence curves for the end points of relapse and NRM. The Cox proportional hazard regression model was used to estimate adjusted cumulative incidence curves. Prognostic factor models for all end points were created using backward selection method considering a P-value of o0.20. The cutoff significance level for all P-values was 0.05. All statistical analyses were performed with Statistical Analysis System statistical software version 9.3 (SAS Institute, Inc., Cary, NC, USA) and R Statistical Software (Foundation for Statistical Computing, Vienna, Austria, http://www.R-project.org).
RESULTS

Patient and donor characteristics
We evaluated 72 patients with R/R HL who received RIC alloHCT and compared the outcomes of 52 patients treated between 2000 and 2008 to 20 patients treated between 2009 and 2013. Patient, disease and treatment characteristics were similar between the groups (Table 1) . For all patients, median age was 31 years (range 6-59), 58% were males and 10% had Karnofsky performance status ⩽ 80%. All patients had advanced HL; primary induction failure was non-significantly less common in recent era (5% vs 23%) possibly due to early intensification of chemotherapy based on interim positron emission tomography. Most patients (82%) had failed prior autoHCT. Median time from diagnosis to alloHCT was 3 years in both groups. Patients received a median of four lines of prior therapy, and there was no significant difference between the two time periods. Graft source included HLA-matched sibling (35%) or UCB (56%) grafts, of which majority received double umbilical cord blood units (90%).
BV was used primarily after 2009 (before 2009 2% vs after 2009 60%) at a median of 4.5 cycles. Four patients received BV as bridge immediately prior to alloHCT, while nine other patients received it at some point in therapy prior to alloHCT. Only one patient had received BV as maintenance therapy after autoHCT. Patients treated more recently (2009-2013) had significantly fewer comorbidities (HCT-CI 0: 60% vs 12%, P o 0.01), and attained higher rates of complete response (CR) pre-HCT (50% vs 23%, P = 0.03) than patients treated from 2000 to 2008. More than half of patients treated with BV pre-transplant experienced CR (54%) compared with 35% CR rate without BV (P = 0.04).
Transplantation outcomes PFS, OS, NRM and relapse after alloHCT are shown in Figure 1 . PFS at 3 years was remarkably improved for patients treated from 2009 to 2013 (49%, 95% CI 26-68%) as compared with 23% (95% CI 13-35%, P = 0.02) for patients treated prior to 2009. Three-year OS was 84% (95% CI 57-94%) vs 50% (95% CI 36-62%, P = 0.01), reflecting lower 1-year NRM (6%, 95% CI 0-16% vs 16%, 95% CI 6-26%; P = 0.15) and 3-year relapse rates (40%, 95% CI 17-63% vs 50%, 95% CI 34-65%; P = 0.11) during the more recent treatment era. In univariate analysis, OS with UCB and HLA-matched sibling transplants were 70%, 95% CI 53-82% and 52%, 95% CI 29-70%, respectively; P = 0.02. Median follow-up of surviving patients was 4.4 years (range 1-12.2 years). In multivariate analysis, treatment in 2009-2013 and chemosensitive disease was associated with improved PFS and OS ( Table 2) . Adjusted OS was comparable between HLA-matched sibling and UCB transplantation (HR 0.65; 95% CI 0.28-1.48; P = 0.30). Factors significant in UVA and multivariate analysis are summarized in Table 2 . HCT-CI ⩾ 1 was associated with increased NRM at 1 year; however this trend was not significant (HCT-CI ⩾ 1 15% vs 0% in patients with HCT-CI = 0; P-0.1). Graft source, KPS, anti-thymocyte globulin use and CMV status did not impact on NRM, relapse rate, PFS or OS. For the entire cohort, median PFS was 26 months (range 1-146) and median OS was 53 months (range 12-146). In multivariate analysis, chemoresistant disease increased mortality (3.83, 95% CI 1.38-10.57), while treatment from 2009 to 2013 was associated with better OS (HR 0.24, 95% CI 0.07-0.79) and PFS (HR 0.46, 95% CI 0.23-0.92; Table 2 ).
Toxicity and GVHD Cumulative incidence of grade 2 to 4 acute GVHD was 44% and declined in the recent time period (25% vs 52%; P = 0.03). The cumulative incidence of chronic GVHD was 33% and also decreased in the recent time period (21% vs 39%). Our group previously reported that GVHD improvements are partially due to increased MMF dosing (up to 3 g per day) in UCB transplants. 18 Patients with evidence of chronic GVHD diagnosed before relapse experienced lower cumulative incidence of relapse at 3 years (27%; 95% CI 5-49%) than patients without chronic GVHD (53%; 95% CI 38-69%; P = 0.02) leading to better 3-year PFS of 46% (95% CI 21-69%) vs 25% (95% CI 15-37%; P = 0.01), suggesting a graft-versus-lymphoma effect. Grade III-IV acute GVHD was associated with worse 3-year OS (22%; 95% CI 7-43% vs 71%, 95% CI 56-81%; P o 0.01).
DISCUSSION
AlloHCT represents the only potentially curative option for HL patients who have R/R HL failing prior autoHCT. Here, we report that survival in patients with advanced R/R HL undergoing alloHCT improved from 2000-2008 to 2009-2013. The survival rate for patients treated after 2009 was above 80%, while NRM has been steadily declined to below 10%. These findings suggest that donor transplantation remains a viable modality for suitable patients with advanced HL.
We defined two time periods for alloHCT for comparison (before and after 2009) based upon availability of BV. The differences in the two groups reflect the efficacy of BV. We showed improved health in potential candidates undergoing alloHCT. Patients in the recent era undergo alloHCT with less frequent use of prior radiation therapy, lower HCT-CI and better disease control. Both improvement in CR rates which occurred in the recent era and the reduced morbidity may be attributable to the use of less toxic BV as a safer and more effective salvage alternative. Additionally, better selection of appropriate candidates for transplantation is possible. Our data suggest that improved survival of patients with HL undergoing alloHCT over time resulted from both reduction in NRM and decreased early relapse. Decreased morbidity and mortality after alloHCT in lymphoma has been attributed to RIC conditioning regimen, advances in supportive care and improved strategies to prevent GVHD. Improvements in supportive measures include better infection prophylaxis and treatment, more comprehensive physical therapy and rehabilitation, and early nutritional evaluation and intervention. We showed that GVHD, both acute and chronic, has declined overtime. The decrease in acute GVHD may be due to more effective GVHD prophylaxis, such as increased MMF dosing in UCB transplants at our institution. 18 Using better HLA-matched UCB units (less 4/6-matched), younger donors and higher proportion receiving anti-thymocyte globulin in the recent era may contribute to decreased chronic GHVD. Also, the potential role of BV in GVHD treatment has been suggested as CD30 appears increased on effector and memory CD8+ T cells and serum soluble CD30 levels are elevated in acute GVHD. Further investigation is needed on whether BV is playing a beneficial role in GVHD control. The efficacy of alloHCT for HL has been controversial. In a few series, two critical prognostic factors for alloHCT that are predictive of outcomes are disease status at transplant and patient comorbidity/performance status. 15, 26 Lack of effective therapies to control advanced HL prior to transplant and comorbidities in heavily treated patients historically limited the benefit of alloHCT. Previous reports on the feasibility of RIC alloHCT for R/R HL in the era prior to 2009 showed 2-year PFS of 23-29% (Fred Hutchinson), 32% (MD Anderson) and 3-year PFS of 22% (Dana Farber): similar to our 3-year PFS of 23% for the time period 2000-2008. [27] [28] [29] Relapse rates were as high as 50%. 11, [29] [30] [31] [32] [33] [34] [35] Our data also support a recent study by Chen et al. 36 from 2014 who reported 2-year OS of 71% and 2-year PFS of 59%, which is comparable to 3-year OS of 84% and 3-year PFS of 49% from our 2009-2013 period. PFS and OS for alloHCT for R/R HL have more than doubled in the recent BV era.
Regarding donor selection, the majority of patients received UCB transplants in this study with excellent long-term outcomes. Although overall numbers were small, we speculate that cord transplants have better graft-versus-tumor effects than matched sibling transplants. This evidence supports smaller recent studies on UCB HCT in HL, which suggest promising survival in patients lacking a suitable adult donor, 37 but caution about higher risk of post-transplant lymphoproliferative disorders with use of anti-thymocyte globulin. 38 At our center, we developed a strategy of prospective EBV titer monitoring and treat EBV viremia preemptively with rituximab with marked reduction of posttransplant lymphoproliferative disorder. 39 Our data concur with recent registry data on alternative donor use in patients with lymphoma 40 and a review by Messer et al. 41 which indicates that unrelated donor and alternative donor sources vs sibling donor alloSCT result in similar outcomes in advanced HL. A limitation of this study is that it is a retrospective and single institution study, yet the design is reflective of actual practice as it has transformed over the last decade. Only one patient had received BV as maintenance therapy after autoHCT given only recent approval of this indication per AETHERA trial. 42 We report on one of the largest series of HL patients treated with RIC alloHCT after BV therapy.
Use of the salvage treatment BV yields improved responses over conventional multi-agent chemotherapy with less toxicity, thereby providing better candidates for alloHCT. The improved disease control prior to transplant most significantly impacts survival, resulting in a doubling of OS. [6] [7] [8] Additionally, the impressive activity of novel regimens, such as PD1 inhibitors, has potential to further enhance responses and survival in HL; however, the timing with respect to alloHCT needs to be judiciously studied. 43 AlloHCT for R/R HL is now a more effective treatment. 
